GLOBE and MFN Pricing: Implications for Cross-Border Drug Development and Transactions
On Oct. 2, 2026, the Centers for Medicare & Medicaid Services (CMS) published the final rule for the Global Benchmark for Efficient Drug Pricing (GLOBE) Model. GLOBE is a mandatory Medicare Part B most-favored-nation (MFN) pricing model that uses international pricing benchmarks to calculate manufacturer rebates for qu
